Trials / Completed
CompletedNCT02869295
A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors
An Open-Label, Multicenter, Dose Escalation And Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumor Malignancies
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Nektar Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a first in human, open-label, sequential dose escalation and expansion Phase 1 study of NKTR-214 in adult patients with locally advanced or metastatic solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NKTR-214 | Participants in the dose escalation cohorts will be treated every 21 days (q21d) or every 14 days (q14d) until tumor progression. |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2018-10-31
- Completion
- 2018-10-31
- First posted
- 2016-08-16
- Last updated
- 2021-07-29
- Results posted
- 2021-07-29
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02869295. Inclusion in this directory is not an endorsement.